Summary

Other Scenarios:

Buyer: Schering AG (ADR) (SHR) Last Price: 120.31 Market Cap.: 22.96B
Target: King Pharmaceuticals, Inc. (KG) Last Price: 16.55 Market Cap.: 4.02B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 870
Biopharmaceuticals 329
Medical Devices 247
Outsourced Services   66

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 79)
  • Cathepsin S Inhibitor
  • Berlex Betapace/Betapace AF (Sotalol Hydrochloride)
  • Berlex Betaseron (Interferon Beta-1b)
  • Berlex AGT-MI (FGF-4 Gene Therapy)
Target (Total: 68)
  • Adrenalin Chloride Solution (Epinephrine)
  • Corgard (Nadolol)
  • Adenocard (Adenosine)
  • Procanbid (Procainamide Hydrochloride)
Buyer
  • Gadofluorine Derivative
  • Berlex Vasovist (Gadofosveset)
  • Medrad Mark V ProVis Injection System
  • Medrad Mark Series
Target
  • Meridian Medical Technologies Prime ECG Electrocardiac Mapping System
  • Binodenoson
  • Meridian Medical Technologies Transtelephonic Blood Pressure Monitors
  • Meridian Medical Technologies CardioBeepers

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 15)
  • Advanced Magnetics, Inc. (AMAG)
  • Biogen Idec Inc. (BIIB)
  • Serono S.A. (ADR) (SRA)
  • Millennium Pharmaceuticals, Inc. (MLNM)
Target (Total: 4)
  • sanofi-aventis (ADR) (SNY)
  • Palatin Technologies, Inc. (PTN)
  • DepoMed, Inc. (DEPO)
  • Inyx, Inc. (IYXI)
Buyer (Total: 5)
  • Millennium Pharmaceuticals, Inc. (MLNM)
  • Cotherix, Inc (CTRX)
  • Sonus Pharmaceuticals, Inc. (SNUS)
  • Favrille, Inc. (FVRL)
Target (Total: 8)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • Cardinal Health, Inc. (CAH)
  • Salix Pharmaceuticals Ltd (SLXP)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 23,098 2,795
Revenue Per Employee 308,724.3 704,366.9
Total Revenue 1,779.7 491.7
Total Expenses 1,566.3 368.5
Other Revenue 0.0 0.0
Cost of Revenue 415.4 106.5
SG&A Expense 738.0 163.1
Research & Development 310.0 38.4
Other Operating Expense 102.9 0.0
Operating Income 213.4 123.2
Unusual Income 0.0 22.7
LT Debt to Capital 5.88 15.12
Fwd P/E n/a 9.76
Fwd P/Rev n/a 2.05
Book Value 4,297.3 2,246.3
Curr Portion of LTD/Cap Lease 30.1 4.3

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

Schering AG is a global research-based company engaged in the discovery, development, manufacture, marketing and sale of pharmaceutical products. The Company operates eight research and development centers in Europe, the United States and Japan, produce products in facilities located in Europe, the United States, Latin America and Asia, and markets and sells its products in over 100 countries worldwide. Its research and development efforts are primarily concentrated on the commercialization of technologies for unmet medical needs in its four core business areas: Gynecology & Andrology, Diagnostic Imaging, Specialized Therapeutics and Oncology. The Company derived approximately 38% of its net sales, during the year ended December 31, 2005, from sales of four key products: Betaferon, sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). Bayer AG gained control of a total of 88% of the Company in June 2006.

Target

King Pharmaceuticals, Inc. (King) is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products. The Company operates through five segments: Branded pharmaceuticals, Meridian Medical Technologies, Royalties, Contract manufacturing and other. King's branded pharmaceutical products can be divided primarily into six therapeutic areas: cardiovascular/ metabolic (including Altace, Corgard, Levoxyl and Cytomel); neuroscience (including Sonata and Skelaxin), hospital/ acute care (including Thrombin-JMI, Bicillin, Synercid and Intal), and other. Meridian Medical Technologies segment consists of its auto-injector business, which includes EpiPen. In March 2006, the Company acquired the rights to market and sell EpiPen throughout Canada until 2015. In addition, the Company manufactures pharmaceutical products under contracts with a variety of pharmaceutical and biotechnology companies.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 76.83 80.34
Operating Margin % 15.61 11.24
Quick Ratio 1.76 2.03
Current Ratio 2.31 2.65
Coverage Ratio 0.02 0.09
Total Assets 7,378.4 3,247.5
Return on Equity % 17.64 7
Return on Assets % 10.27 4.84
Cash+ ST Inv. Per Share 8 3.78
Total Debt 298.7 404.3
Total Debt to Equity % 6.95 18
Total Debt to Tangible Equity % 8.61 33.68
Debt to Asset % 4.05 12.45

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
  
Medical Devices
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
  
Neurology
The Neurology Subsector includes medical devices that diagnose, monitor and treat neurological disorders.
  
Oncology
The Oncology Subsector includes medical devices that detect and treat cancers.
  
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
  
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
  
Outsourced Services  
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of allergic reactions in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Systemic  
Anaphylactic Shock  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that treat allergic shock by stimulating alpha and beta adrenergic receptors.

Target Products:

  • Adrenalin Chloride Solution (Epinephrine)
  
Cardiovascular System
Heart Disorders
Angina  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.

Target Products:

  • Corgard (Nadolol)
  
Arrhythmia
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction

Target Products:

  • Adenocard (Adenosine)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Berlex Betapace/Betapace AF (Sotalol Hydrochloride)
  
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.

Target Products:

  • Procanbid (Procainamide Hydrochloride)
  
Heart Failure (HF)  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.

Target Products:

  • Altace (Ramipril)
  
Complications  
Edema  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Berlex Betaseron (Interferon Beta-1b)
  • Berlex AGT-MI (FGF-4 Gene Therapy)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Vascular Disorders
Hypertension  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.

Target Products:

  • Altace (Ramipril)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Target Products:

  • Corgard (Nadolol)
  
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Corzide (Nadolol/Bendroflumethiazide)
  
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Berlex Refludan (Lepirudin)
  
Dermatology
Acne  
Rosacea  
Azelaic Acid
Therapeutics that treat and prevent rosacea caused by bacteria.

Buyer Products:

  • Berlex Finacea (Azelaic Acid)
  
Lesion/Scaling Disorders  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site, as well as prevent the growth of bacteria.

Target Products:

  • Cortisporin (Neomycin/Polymyxin B Sulfates/Hydrocortisone Acetate) Cream/Ointment
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • CRA-028129 (Cathepsin S Inhibitor)
  • Berlex Tisocalcitate (Calcitriol Analog)
  
Digestive System
Gastrointestinal Tract Disorders
Gastroesophageal Disorders  
Nausea/Vomiting  
Antiemetic Agents
Therapeutics that treat nausea or vomiting by acting locally on the hyperactive gastrointestinal wall.

Target Products:

  • Tigan (Trimethobenzamide Hydrochloride)
  
Intestinal Disorders  
Inflammatory Bowel Disease (IBD)  
Crohn`s Disease  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Stomatognathic Disorders  
Mucositis  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat mucositis by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
  
Endocrinology/Metabolism
Adrenal Gland Disorders  
Adrenocortical Insufficiency  
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.

Target Products:

  • Florinef (Fludrocortisone Acetate)
  
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Target Products:

  • Pitressin (Vasopressin)
  
General Hormone Treatments  
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.

Target Products:

  • Delestrogen (Estradiol Valerate Injection, USP)
  • Menest (Esterified Estrogens Tablets)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Target Products:

  • MRE0094 (Adenosine A2a Receptor Agonist)
  
Pituitary Gland Disorders  
Pituitary Hyperthyroidism (TSH-Induced)  
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.

Target Products:

  • Levoxyl (Levothyroxine Sodium)
  
Reproductive Disorders
Hypoestrogenism  
Hormonal Treatments  
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)
  
Hypogonadism
Female
Hormonal Treatments
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Menest (Esterified Estrogens Tablets)
Menopause
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Menest (Esterified Estrogens Tablets)
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.

Buyer Products:

  • Berlex Climodien 1/2 (Estradiolvalerate/Dienogest)
  • Berlex Climara Pro (Levonorgestrel/Estradiol Transdermal)
  • Berlex Angeliq (Drospirenone/Estradiol)
  
Progestins
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Levonorgestrel Intrauterine System
  
Thyroid Gland Disorders  
Hyperthyroidism  
Thyroid Hormone Synthesis Inhibitors
Therapeutics that stop the production of thyroid hormones.

Target Products:

  • Tapazole (Methimazole)
  
Hypothyroidism  
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.

Target Products:

  • Levoxyl (Levothyroxine Sodium)
  • Triostat (Liothyronine Sodium)
  • Cytomel (Liothyronine Sodium)
  
Hematology  
White Blood Cell (WBC) Disorders  
Neutropenia  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Immunology  
Autoimmune Disorders  
Inflammatory Bowel Disease (IBD)  
Crohn`s Disease  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Multiple Sclerosis (MS)  
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that downregulates the antibody response of the immune system.

Buyer Products:

  • Berlex Betaseron (Interferon Beta-1b) For SC Injection
  • Berlex Betaseron (Interferon Beta-1b)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Berlex Tisocalcitate (Calcitriol Analog)
  • Berlex Campath (Alemtuzumab)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.

Target Products:

  • Coly-Mycin M Parenteral (Colistimethate Sodium)
  
Carbacephems
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Target Products:

  • Lorabid (Loracarbef)
  
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.

Target Products:

  • Bicillin C-R/C-R 900/300/C-R Pediatric (Penicillin G Benzathine/Penicillin G Procaine Injectable Suspension)
  • Bicillin L-A/L-A Pediatric (Penicillin G Benzathine Injectable Suspension)
  • Penicillin G Procaine Injectable Suspension
  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Target Products:

  • Synercid (Quinupristin/Dalfopristin)
  
Narrow Spectrum  
Dermatology  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotics)
Therapeutics that treat bacterial infections of the skin with a steroidal compound and a compound that kills or inhibits the growth of bacteria.

Target Products:

  • Cortisporin (Neomycin/Polymyxin B Sulfates/Hydrocortisone Acetate) Cream/Ointment
  
Skin/Soft Tissue Infections  
Sulfonamides
Therapeutics that treat specific bacterial infections by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
  
Musculoskeletal System  
Skin/Soft Tissue Infections  
Sulfonamides
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
  
Ophthalmology  
Ocular Infections  
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.

Target Products:

  • Neosporin Ophthalmic (Neomycin Sulfate B/Polymyxin Sulfate B/Gramicidin) Ointment/Solution Sterile
  
Aminoglycosides/Polypeptides/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis, damaging the cell membrane, and suppressing the full immune response.

Target Products:

  • Cortisporin Opthalmic (Neomycin/Polymyxin B Sulfates/Bacitracin Zinc/Hydrocortisone) Ointment/Suspension Sterile
  
Polypeptides
Therapeutics that treat bacterial infections of the eye by damaging the cell membrane.

Target Products:

  • Polysporin (Bacitracin Zinc/Polymyxin B Sulfate)
  
Otolaryngology (Ear/Nose/Throat)  
External Ear Canal Infections  
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that treat bacterial infections of the external auditory canal with a steroidal compound and by killing or inhibiting the growth of microorganisms.

Target Products:

  • Cortisporin-TC Otic (Colistin Sulfate/Neomycin Sulfate/Thonzonium Bromide/Hydrocortisone Acetate)
  • Cortisporin Otic (Neomycin/Polymyxin B Sulfate/Hydrocortisone) Solution/Suspension Sterile
  • Coly-Mycin S Otic (Colistin Sulfate/Neomycin Sulfate/Thonzonium Bromide/Hydrocortisone Acetate)
  • Pediotic Suspension Sterile (Neomycin/Polymyxin B Sulfates/Hydrocortisone)
  
Otitis Media  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
  
Respiratory System  
Bronchitis  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
  
Pneumonia  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
  
Urology  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Aminoglycosides
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by inhibiting bacterial protein synthesis.

Target Products:

  • Neosporin G.U. Irrigant (Neomycin Sulfate/Polymyxin B Sulfate)
  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
  
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.

Target Products:

  • Proloprim (Trimethoprim) Tablets
  
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Amebiasis  
Aminoglycosides
Therapeutics that treat infections by an amoeba by inhibiting protozoal protein synthesis.

Target Products:

  • Humatin (Paramomycin Sulfate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Human Papilloma Virus Vaccine
  
Viral  
DNA Viruses  
Herpesvirus  
Herpes Simplex Type 1  
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA blocking the action of an essential enzyme.

Target Products:

  • Viroptic Ophthalmic Solution (Trifluridine)
  
Herpes Simplex Type 2  
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by blocking the action of an essential enzyme.

Target Products:

  • Viroptic Ophthalmic Solution (Trifluridine)
  
Musculoskeletal System
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Skeletal Disorders
Bone Disorders
Osteoporosis
Hormonal Treatments
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Berlex Menostar (Estradiol)
  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Delestrogen (Estradiol Valerate Injection, USP)
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Berlex Climara Pro (Levonorgestrel/Estradiol Transdermal)
  
Neurology
Neurological Disorders  
Epilepsy  
Status Epilepticus  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat status epilepticus by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Vanquix (Diazepam Auto-Injection)
  
Neuromuscular Disorders
Multiple Sclerosis (MS)  
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that down regulates the antibody response of the immune system.

Buyer Products:

  • Berlex Betaseron (Interferon Beta-1b)
  • Berlex Betaseron (Interferon Beta-1b) For SC Injection
  
Parkinson`s Disease (PD)  
Adjunctive Treatments  
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.

Target Products:

  • Kemadrin (Procyclidine Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Berlex Spheramine
  • Berlex Campath (Alemtuzumab)
  
Psychiatric Disorders
Mood Disorders  
Premenstrual Dysphoric Disorders  
Estrogens/Progestins
Therapeutics that treat premenstrual dysphoric disorders by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus.

Buyer Products:

  • Berlex YAZ (Drospirenone/Ethinyl Estradiol)
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Target Products:

  • Sonata CIV (Zaleplon)
  
Obstetrics/Gynecology
Child Birth/Pregnancy
Induction/Cervical Ripening  
Oxytocic Agents
Therapeutics that induce contractions by increasing the levels of intracellular calcium in the uterine smooth muscle thus mimicking uterine contractions and transiently impeding uterine blood flow.

Target Products:

  • Pitocin (Oxytocin)
  
Prevention (Contraception)  
Contraceptives (Birth Control)  
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Buyer Products:

  • Berlex Tri-Levlen 21/Tri-Levlen 28 (Levonorgestrel/Ethinyl Estradiol Tablets)
  • Berlex Yasmin (Drospirenone/Ethinyl Estradiol)
  • Berlex E2/DNG Pill (Estradivalerate/Dienogest)
  • Berlex FC Patch (Gestodene/Ethinyl Estradiol)
  • Berlex YAZ (Drospirenone/Ethinyl Estradiol)
  • Berlex Levlen 21/Levlen 28 (Levonorgestrel/Ethinyl Estradiol Tablets)
  • Berlex Levlite (Levonorgestrel/Ethinyl Estradiol Tablets)
  
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system

Buyer Products:

  • Berlex Mirena (Levonorgestrel-Releasing Intrauterine Device)
  
Female Genital Disorders
Endometriosis  
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.

Buyer Products:

  • Berlex Endometrion (Dienogest)
  
Ovarian
Hypogonadism
Hormonal Treatments
Estrogens
These are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Menest (Esterified Estrogens Tablets)
  • Delestrogen (Estradiol Valerate Injection, USP)
Vulvovaginal
Atrophy
Hormonal Treatments
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Delestrogen (Estradiol Valerate Injection, USP)
  • Menest (Esterified Estrogens Tablets)
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Bremelanotide/PT-141 (Alpha Melanocyte-Stimulating Hormone Analog)
  
Oncology
Breast Cancer
Metastatic  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • TOCOSOL Paclitaxel (S-8184)
  
Palliative Agents  
Hormonal Treatments  
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.

Target Products:

  • Menest (Esterified Estrogens Tablets)
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Localized  
Vascular Endothelial Growth Factor Receptor Inhibitor (VEGFR)
Therapeutics that treat colorrectal cancer by binding specifically to the tyrosine kinase domain of vascular endothelial growth factor receptor (VEGFR) and inhibiting the formation of blood vessels around tumor cells.

Buyer Products:

  • Berlex PTK787 (Vatalanib)
  
Metastatic  
Vascular Endothelial Growth Factor Receptor Inhibitor (VEGFR)  
Hematology  
Leukemia  
Lymphoid  
Chronic  
Lymphocytic (CLL)  
Antimetabolite Agents  
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.

Buyer Products:

  • Berlex Fludara (Fludarabine Phosphate)
  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.

Buyer Products:

  • Berlex Campath (Alemtuzumab)
  
Palliative Agents  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Lymphoma  
Hodgkin`s Disease  
Palliative Agents  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphoma characterized by the presence of Reed-Sternberg cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Non-Hodgkin`s Lymphoma (NHL)  
Palliative Agents  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphomas of B-cells and T-cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Musculoskeletal System  
Metastatic  
Osteolytic Bone Metastases  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat and manage bone cancers that have spread beyond their original tumor site by preventing the loss of bone mass followed by deposition of new bone which can result in entrapped tumors below the new bone surface.

Buyer Products:

  • Berlex Bonefos (Clodronate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • ZK-EPO (Epothilone)
  • Berlex MS-275 (Histone Deacytelators)
  • Oral Multi-target Tumor Growth Inhibitor (MTGI)
  • TOCOSOL Paclitaxel (S-8184)
  • Berlex PTK787 (Vatalanib)
  • Berlex MS209 (Multidrug Resistance Modulator)
  
Urology
Prostate Cancer  
Palliative Agents  
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.

Target Products:

  • Menest (Esterified Estrogens Tablets)
  
Uterine Cancer  
Uterine Fibroids (Leiomyoma, Uterus)  
Progestins Receptor Modulators
Therapeutics that treat and manage non-cancerous tumors of the uterus by modulating the effects of progesterone.

Buyer Products:

  • Berlex Asoprisnil
  
Ophthalmology  
Degenerative Disorders  
Irritation/Inflammation  
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.

Target Products:

  • Polysporin (Bacitracin Zinc/Polymyxin B Sulfate)
  • Neosporin Ophthalmic (Neomycin Sulfate B/Polymyxin Sulfate B/Gramicidin) Ointment/Solution Sterile
  
Antibacterial Agents/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat infections by inhibiting bacterial replication as well as prevent cells that cause inflammation from adhering to the inflammation site.

Target Products:

  • Cortisporin Opthalmic (Neomycin/Polymyxin B Sulfates/Bacitracin Zinc/Hydrocortisone) Ointment/Suspension Sterile
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.

Target Products:

  • Ketalar CIII (Ketamine Hydrochloride)
  
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.

Target Products:

  • Brevital Sodium C-IV (Methohexital Sodium)
  
Primary  
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.

Target Products:

  • Brevital Sodium C-IV (Methohexital Sodium)
  
Narcotics  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Remoxy (Time-Release Oxycodone)
  • Avinza (Morphine Sulfate ER Capsules)
  
Non-Narcotics  
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.

Target Products:

  • Skelaxin (Metaxalone)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • PTI-202
  • T-62
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Acute Treatments  
Bronchodilators  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Target Products:

  • Adrenalin Chloride Solution (Epinephrine)
  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
  
Prophylactic Treatments  
Mast Cell Stabilizers
Therapeutics that treat asthma by inhibiting mast cell degranulation.

Target Products:

  • Intal HFA (Cromolyn Sodium)
  • Tilade (Nedocromil Sodium)
  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
  
Bronchitis  
Complications  
Bacterial Infections  
Antibacterial Agents (Antibiotics)  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Target Products:

  • Septra (Sulfamethoxazole/Trimethoprim) IV Infusion/Tablets/Suspension
  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
  
Bronchospasm  
Bronchodilators  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Target Products:

  • Adrenalin Chloride Solution (Epinephrine)
  
Emphysema  
Prophylactic Treatments  
Phosphodiesterase Inhibitors (PDE Inhibitors)
Therapeutics that inhibit the break down of phosphodiesters thereby increasing levels of Nitric Oxide which help in relaxing smooth muscles in the lungs.

Target Products:

  • Quibron-T / Quibron-T/SR (Theophylline - Accudose)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Anticholinergic Agents/Opioids
Therapeutics that treat coughs and colds by relieving pain and fever as well as suppressing cough.

Target Products:

  • Tussigon Tablets CIII (Hydrocodone Bitartrate/Homatropine Methylbromide)
  
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.

Target Products:

  • Nucofed Capsules/Syrup CIII (Codeine Phosphate/Pseudoephedrine Hydrochloride)
  
Decongestants/Antitussives/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and helping in the ejection of the mucous.

Target Products:

  • Nucofed Expectorant/Pediatric Expectorant (Codeine Phosphate/Pseudoephedrine Hydrochloride/Guaifenesin)
  
Surgery  
General  
Hemorrhage  
Coagulating Agents (Coagulants)
Therapeutics that treat bleeding during a surgical procedure by promoting blood clotting.

Target Products:

  • Thrombin JMI
  
Toxicology  
Chemical Poisoning  
Nerve Gas  
Anticholinergic Agents
Therapeutics that treat toxicity due to nerve agent/gas by antagonizing the muscarine-like actions of acetylcholine and other choline esters.

Target Products:

  • AtroPen (Atropine)
  • Meridian Medical Technologies Duodote (Atropine/Pralidoxime Chloride Injection)
  
Transplantation  
Bone Marrow  
Complications  
Neutropenia  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Peripheral Blood Progenitor Cell Transplant (PBPCT)  
Recovery  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Urology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Progestogen Etonogestrel
  • Berlex Oxybutynin Releasing Vaginal Ring

Target Products:

  • Bremelanotide/PT-141 (Alpha Melanocyte-Stimulating Hormone Analog)
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Edema  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.

Target Products:

  • Thalitone (Chlorthalidone)
  
Renal Insufficiency  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that delay or treat kidney disease by inhibiting the renin-angiotensin system.

Target Products:

  • Altace (Ramipril)
  
Wound Management  
Burns  
Complications  
Infections  
Antibacterial Agents (Antibiotics)  
Sulfonamides
Therapeutics that treat bacterial infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
  
Antifungal Agents  
Sulfonamides
Therapeutics that treat fungal infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.

Target Products:

  • Silvadene (Silver Sulfadiazine)
  
Medical Devices
Cardiology
Diagnostic
Imaging  
Magnetic Resonance Imaging (MRI)  
Contrast Agents
A drug that is introduced into a patient to attain better image quality.

Buyer Products:

  • Gadofluorine Derivative
  • Berlex Vasovist (Gadofosveset)
  
X-Ray  
Angiography  
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.

Buyer Products:

  • Medrad Mark V ProVis Injection System
  • Medrad Mark Series
  
Monitoring
Monitors
Electrocardiogram (ECG/EKG)  
Interpretive/Analysis
Specialized electrocardiogram devices that facilitate certain diagnostic functions and analysis.

Target Products:

  • Meridian Medical Technologies Prime ECG Electrocardiac Mapping System
  
Stress/Exercise Test
Instruments used to evaluate the cardiopulmonary system during exercise.

Target Products:

  • Binodenoson
  
Telemetry  
Telemetry Systems
Complete systems or devices used to facilitate transfer of vitals monitoring data from the patient's site to a central monitor.

Target Products:

  • Meridian Medical Technologies Transtelephonic Blood Pressure Monitors
  • Meridian Medical Technologies CardioBeepers
  
Vitals/Multiple Parameter  
Electrocardiogram (ECG/EKG)/Pulse Oximeter (SpO2)/ Multiple Vitals  
Portable
Device that measures, records, and displays the electrical signals of the heart, the oxygen concentration in the blood, the blood pressure with direct access to an artery and blood pressure with out direct access to an artery and can be moved around with the patient.

Buyer Products:

  • Medrad 9500 Vital Signs Patient Monitor
  
Clinical Diagnostics  
Immunoassays  
Reagents  
Test Kits  
Bacterial  
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.

Target Products:

  • Aplisol (Tuberculin Purified Protein Derivative)
  
Drug Delivery  
Percutaneous (Subcutaneous/Intramuscular/Intravenous)  
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.

Target Products:

  • Meridian Medical Technologies Auto-Injector Technology
  
Neurology  
Surgical  
Region Specific  
Brain  
Stereotactic Surgery  
Guidance/ Planning Systems
Imaging equipment and/or computer systems that create a 3D map of the interior of the brain facilitating stereotactic surgery.

Buyer Products:

  • Medrad SimpliCT
  
Oncology  
Diagnostic  
Imaging  
MRI  
Contrast Agents
A drug that is introduced into a patient to attain better MRI image quality.

Buyer Products:

  • Berlex Vasovist (Gadofosveset)
  
Radiology
Computed Tomography (CT) Scan  
Accessories  
CT Contrast Injectors
Devices that mechanically push contrast agent into the patient.

Buyer Products:

  • Medrad EnVision CT
  • Medrad Stellant CT
  • Medrad Vistron CT
  
Syringes
Disposables used in contrast injection pumps.

Buyer Products:

  • Medrad Angiomat 3000/6000/6000CT
  • Medrad 100/200/300 Series
  • Medrad EnVision CT Front Load
  • Medrad MCT Plus Front Load
  • Medrad Viamonte-Hobbs 2000
  • Medrad Vistron CT Front Load
  
Contrast Agents  
Injectable
CT Scan contrast agents administered by injection.

Buyer Products:

  • Berlex Neotect (Kit for the Preparation of Technetium Tc 99m Depreotide Injection)
  • Berlex Acutect (Kit for the Preparation of Technetium Tc 99m Apcitide Injection)
  • Berlex Ultravist (Iopromide)
  
MRI  
Accessories  
Needle Systems
Injection systems used to deliver MRI contrast agents.

Buyer Products:

  • Medrad Spectris Solaris MR Injection Series
  • Medrad Continuum MR Compatible Infusion System
  • Medrad Spectris MR
  
Coils  
Closed MRI  
General Purpose
A closed MRI system that is designed to be used for multiple purpose imaging studies.

Buyer Products:

  • Medrad Multi-Purpose Array
  
Region Specific  
Abdominal
A coil that is placed on the abdomen to attain an image.

Buyer Products:

  • Medrad MRInnervu
  • Medrad Torso Array
  
Breast
A coil that is placed on the breast to attain an image of it.

Buyer Products:

  • Medrad Breast Coil/Array
  
Head/Neck
A coil that is placed on or around the head/neck to attain an image of it.

Buyer Products:

  • Medrad Neurovascular Array
  • Medrad Anterior Neck Coil
  
Lower Extremity
A coil that is placed on the lower extremity to attain an image of it.

Buyer Products:

  • Medrad Extremity Array
  
Spine
A coil that is placed near the spine to attain an image of it.

Buyer Products:

  • Medrad Quadrature Cervical Thoracic-Lumbar Array
  
Upper Extremity
A coil that is placed on an upper extremity to attain an image of it.

Buyer Products:

  • Medrad Extremity Array
  • Medrad Shoulder Coil
  
Vascular
A coil that is placed near a vessel to attain an image of it.

Buyer Products:

  • Medrad Gore Cardiovascular Array
  
Contrast Agents  
Injectable
A contrast agent that gets introduced to the body via a needle or IV.

Buyer Products:

  • Berlex Eovist
  • Berlex Magnevist (Gadopentetate Dimeglumine)
  • Berlex Feridex I.V. (Ferumoxide)
  • Berlex Vasovist (Gadofosveset)
  • Berlex SHU 555C
  • Berlex Primovist (Gadoxetic Acid)
  • Berlex Gadovist (Gadobutrol)
  • Berlex Resovist
  
Nuclear  
Gamma Camera  
Contrast Agents  
Radionuclides  
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.

Target Products:

  • Adenoscan
 
Ultrasound  
Accessories  
Aspiration Needles
Biopsy needles that have special properties allowing ultrasound guidance.

Buyer Products:

  • Medrad Pulsar Injection System
  
X-Ray  
Contrast Agents  
Injectable
Introduced to the body via a needle.

Buyer Products:

  • Berlex Ultravist (Iopromide)
  • SF-64 (Omocianine)
  
Urology  
Diagnostic  
Imaging  
MRI  
Contrast Agents
A drug that is introduced into a patient to attain better MRI image quality.

Buyer Products:

  • Berlex Vasovist (Gadofosveset)
  
Vascular  
Diagnostic  
Imaging  
X-Ray  
Angiography  
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.

Buyer Products:

  • Medrad Mark Series
  
Outsourced Services  
Development/Manufacturing Services  
Chemistry Services
Outsourced companies that provide medicinal chemistry, organic synthesis, process research, cGMP synthesis, and analytical services to the biopharmaceutical industry.

Target Products:

  • Meridian Medical Technologies Contract Development Services
  
Contract Manufacturing Organizations (CMO)  
Medical Devices
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.

Target Products:

  • Meridian Medical Technologies Contract Manufacturing Services
  
Pharmaceuticals  
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.

Target Products:

  • King Pharmaceuticals Contract Manufacturing Services
  • Meridian Medical Technologies Contract Manufacturing Services
  
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.

Target Products:

  • King Pharmaceuticals Contract Manufacturing Services
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Medicis Pharmaceutical Corporation n/a 2,078.941 n/a 48.94 6.28 5.89 8.62
Neurocrine Biosciences, Inc. n/a 378.840 n/a -3.13 8.63 11.84 1.16
Buyer
  Roche Holding Ltd. (ADR) n/a 157,245.145 34.89 24.82 5.69 n/a 8.62
Genentech, Inc. n/a 84,941.939 45.71 40.64 10.04 9.42 12.00
Target
  Pfizer Inc. n/a 193,888.862 15.37 13.35 4.01 4.07 8.31
GlaxoSmithKline plc (ADR) n/a 148,888.977 14.59 14.60 3.36 3.42 14.57
sanofi-aventis (ADR) n/a 116,539.433 30.70 13.50 3.12 3.28 n/a
Wyeth n/a 64,708.887 15.89 15.26 3.26 3.22 6.16
Bristol Myers Squibb Co. n/a 48,125.833 21.70 23.78 2.57 2.72 9.97
Forest Laboratories, Inc. n/a 15,661.993 21.49 18.71 4.93 4.80 5.94
Shire plc (ADR) n/a 10,059.401 36.11 35.11 5.70 5.62 11.70
Biovail Corporation (USA) n/a 2,757.746 13.24 6.68 2.63 2.61 6.01
Watson Pharmaceuticals, Inc. n/a 2,568.873 40.88 21.64 1.45 1.37 2.28
Medicis Pharmaceutical Corporation n/a 2,078.941 n/a 48.94 6.28 5.89 8.62
Cubist Pharmaceuticals, Inc. n/a 1,191.527 n/a 182.58 6.80 6.04 404.46
Sciele Pharma Inc. n/a 814.257 18.26 19.63 2.90 2.83 12.82
Omrix Biopharmaceuticals, Inc. n/a 457.283 27.28 20.99 8.46 7.54 10.16
Impax Laboratories Inc. n/a 444.484 380.49 22.65 3.95 n/a 7.58
Neurocrine Biosciences, Inc. n/a 378.840 n/a -3.13 8.63 11.84 1.16
Vanda Pharmaceuticals Inc. n/a 306.920 n/a -3.40 n/a n/a 8.31
Somaxon Pharmaceuticals, Inc. n/a 254.085 n/a -5.28 n/a 41.35 4.32
Lannett Company, Inc. n/a 165.457 33.79 23.45 2.29 1.88 2.58
Avigen, Inc. n/a 147.326 n/a -5.61 12.17 1,503.33 2.15
Medicure Inc. (USA) n/a 130.746 n/a n/a 160.11 n/a 15.27
Advancis Pharmaceutical Corporation n/a 127.437 n/a -3.38 24.56 18.67 n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Advanced Magnetics, Inc. 47.00% 683.619 n/a -60.21 250.37 498.12 15.35
Biogen Idec Inc. n/a 17,365.400 105.62 24.29 6.66 6.52 5.90
Serono S.A. (ADR) n/a 13,657.170 19.97 19.08 4.99 4.87 5.65
Millennium Pharmaceuticals, Inc. n/a 3,612.192 n/a -286.50 7.70 7.57 6.47
Medarex, Inc. n/a 1,644.559 n/a -9.34 29.36 34.19 4.46
Crucell N.V. (ADR) n/a 1,397.634 n/a -13.44 14.23 7.49 3.80
Dendrite International, Inc. n/a 511.778 n/a 53.45 1.22 1.23 3.77
Penwest Pharmaceuticals n/a 422.847 n/a -13.24 114.56 110.91 8.71
OPNET Technologies, Inc. n/a 332.082 60.23 43.76 3.79 3.42 3.71
Peregrine Pharmaceuticals n/a 246.122 n/a n/a 72.26 n/a 8.49
EPIX Pharmaceuticals, Inc. n/a 125.667 n/a -2.99 20.31 15.99 n/a
Pharmacopeia Drug Discovery, Inc. n/a 85.337 n/a -2.54 4.44 4.80 4.51
Bioject Medical Technologies Inc. n/a 14.847 n/a n/a 1.55 n/a 2.54
Tripos, Inc. n/a 7.810 n/a n/a 0.18 n/a 0.38
Valentis, Inc. n/a 7.687 n/a n/a 10.58 n/a 3.16
Target
  sanofi-aventis (ADR) n/a 116,539.433 30.70 13.50 3.12 3.28 n/a
Palatin Technologies, Inc. n/a 156.476 n/a -5.37 8.01 4.24 15.50
DepoMed, Inc. n/a 147.841 n/a -4.12 19.25 12.18 n/a
Inyx, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Millennium Pharmaceuticals, Inc. n/a 3,612.192 n/a -286.50 7.70 7.57 6.47
Cotherix, Inc n/a 384.762 n/a -14.06 6.41 5.57 4.49
Sonus Pharmaceuticals, Inc. n/a 213.430 n/a -7.65 8.62 8.95 4.34
Favrille, Inc. n/a 101.704 n/a -2.25 n/a n/a 1.89
Accentia Biopharmaceuticals, Inc n/a 100.865 n/a -2.34 3.72 3.31 n/a
Target
  McKesson Corporation 27.00% 14,259.786 17.26 17.85 0.16 0.15 3.50
AmerisourceBergen Corp. 14.00% 9,114.743 19.49 18.56 0.15 0.15 2.20
Cardinal Health, Inc. n/a 25,195.796 24.17 16.98 0.30 0.28 7.48
Salix Pharmaceuticals Ltd n/a 670.110 45.55 22.45 3.40 3.29 3.91
QLT Inc. (USA) n/a 666.782 n/a 27.06 3.57 3.89 2.06
Vascular Solutions, Inc. n/a 112.448 n/a -43.88 2.76 2.60 8.27
Government - United States n/a n/a n/a n/a n/a n/a n/a
Merck KGaA n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pfizer Inc. n/a 193,888.862 15.37 13.35 4.01 4.07 8.31
Novartis AG (ADR) n/a 137,962.635 20.11 18.92 3.81 3.74 3.58
AstraZeneca plc (ADR) n/a 89,001.730 15.25 14.69 3.48 3.38 8.92
Abbott Laboratories n/a 72,061.862 22.74 18.94 3.23 3.25 28.77
3M Company n/a 59,756.110 17.39 17.98 2.66 2.62 9.21
Koninklijke Philips Electronics NV (ADR) n/a 43,560.190 6.91 33.58 1.23 1.30 1.83
Biogen Idec Inc. n/a 17,365.400 105.62 24.29 6.66 6.52 5.90
Genzyme Corporation n/a 17,130.299 47.84 29.82 5.60 5.42 5.69
Serono S.A. (ADR) n/a 13,657.170 19.97 19.08 4.99 4.87 5.65
Target
  sanofi-aventis (ADR) n/a 116,539.433 30.70 13.50 3.12 3.28 n/a
Wyeth n/a 64,708.887 15.89 15.26 3.26 3.22 6.16
Eli Lilly & Co. n/a 60,992.647 18.88 17.15 3.98 3.94 4.67
Barr Pharmaceuticals, Inc. n/a 5,376.860 17.57 15.38 4.02 3.70 4.32
Arrow International, Inc. n/a 1,564.867 27.94 22.88 3.25 2.99 3.58
Salix Pharmaceuticals Ltd n/a 670.110 45.55 22.45 3.40 3.29 3.91
QLT Inc. (USA) n/a 666.782 n/a 27.06 3.57 3.89 2.06
Pain Therapeutics, Inc. n/a 384.754 43.88 58.13 7.31 6.66 4.73
Palatin Technologies, Inc. n/a 156.476 n/a -5.37 8.01 4.24 15.50
DepoMed, Inc. n/a 147.841 n/a -4.12 19.25 12.18 n/a
Vascular Solutions, Inc. n/a 112.448 n/a -43.88 2.76 2.60 8.27
Inyx, Inc. n/a n/a n/a n/a n/a n/a n/a
Suntory Group n/a n/a n/a n/a n/a n/a n/a
United Research Laboratories and Mutual Pharmaceutical Company n/a n/a n/a n/a n/a n/a n/a
Merck KGaA n/a n/a n/a n/a n/a n/a n/a
Astellas Pharma Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 7,009.5 1,898.9 8,908.3
Other Revenue 0.0 0.0 0.0
Total Revenue 7,009.5 1,898.9 8,908.3
Cost of Revenue 1,624.0 373.2 1,997.3
SG&A Expense 2,887.9 642.2 3,530.1
Depreciation & Amortization 0.0 145.1 145.1
Research & Development 1,283.9 123.9 1,407.8
Interest Expense 0.0 0.0 0.0
Other Operating Expense 119.2 -0.2 119.0
Unusual Expense (Income) 0.0 401.2 401.2
Total Expenses 5,915.1 1,685.4 7,600.5
Operating Income 1,094.4 213.5 1,307.9
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 18.8 18.6 37.4
Other, Net 28.9 -0.6 28.3
Income Before Taxes 1,142.1 231.4 1,373.5
Income Taxes 384.0 74.1 458.2
Income After Taxes 758.1 157.3 915.4
Minority Interest (IS) -5.0 0.0 -5.0
Net Income - Excl. Xord. Items 753.0 157.3 910.4
Discontinued Operations 0.0 0.1 0.1
Net Income - Incl. Xord. Items 753.0 157.4 910.4
Income Avail. to Common 753.0 157.4 910.4
Share Items
Basic Avg. Shares Outstanding 192.4 242.3 434.7
Basic EPS - Excl. Xord. Items 3.91 0.65 2.09
Basic EPS - Incl. Xord. Items 3.91 0.65 2.09
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 192.4 242.8 435.2
F.D. EPS - Excl. Xord. Items 3.91 0.65 2.09
F.D. EPS - Incl. Xord. Items 3.91 0.65 2.09
Dividends Per Common Share 1.51 0.00 1.51
Balance Sheet
Assets
Cash and Equivalents 1,445.8 138.1 1,583.9
ST Investments 94.1 779.5 873.7
Accounts Receivable 1,865.0 255.7 2,120.8
Inventory 1,070.6 186.8 1,257.3
Prepayments and Advances 0.0 102.4 102.4
Other Current Assets 0.0 69.2 69.2
Current Assets 4,475.5 1,531.6 6,007.1
Accum D&A 0.0 0.0 0.0
PPE, Net 1,408.2 303.8 1,712.0
Goodwill & Intangibles 829.6 1,046.0 1,875.6
Long Term Investments 268.6 13.5 282.1
Other Assets 0.0 0.0 0.0
Other LT Assets 396.6 352.6 749.2
Total Assets 7,378.4 3,247.5 10,626.0
Liabilities
Accounts Payable 0.0 80.8 80.8
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 0.0 471.7 471.7
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 30.1 4.3 34.4
Other (Current) Liabilities 1,907.7 20.6 1,928.3
Current Liab. 1,937.8 577.4 2,515.2
LT Debt 268.6 400.0 668.6
Total LT Debt 268.6 400.0 668.6
Minority Interest (BS) 23.8 0.0 23.8
Other LT Liab. 850.9 23.9 874.8
Total Liabilities 3,081.2 1,001.3 4,082.4
Shareholders Equity
Common Stock 243.5 1,238.5 1,482.0
Additional Paid in Capital 419.2 0.0 419.2
Retained Earnings 3,638.4 1,006.9 4,645.3
Treasure Stock -3.8 0.0 -3.8
Other Equity 0.0 0.8 0.8
Total Equity 4,297.3 2,246.3 6,543.6
Total Liab. & Equity 7,378.4 3,247.5 10,626.0
Shares Outstanding 190.8 243.1 433.9
Cash Flow
Operating Cash Flow
CF Net Income 758.1 0.0 758.1
CF Depreciation 430.5 0.0 430.5
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items -86.6 -1.2 -87.8
Change in Working Capital 356.4 413.1 769.6
Total Cash From Operating Activities 1,458.4 411.9 1,870.3
Investing Cash Flow (not calculated)
Capital Expenditures -377.8 -95.7 -473.4
Other Investing Cash Flows -7.5 -316.7 -324.2
Total Cash From Investing Activities -385.3 -412.3 -797.6
Financing Cash Flow (not calculated)
Dividends Paid -291.2 0.0 -291.2
Purchase Or Sale of Stock 74.0 7.0 81.1
Purchase and Retirement of Debt 0.0 61.6 61.6
Other Financing Cash Flow -579.8 -10.4 -590.2
Total Cash From Financing Activities -797.0 58.2 -738.7
Exchange Rate Effects -12.6 0.0 -12.6
Net Change in Cash 263.6 57.8 321.4
Cash Taxes Paid 252.3 107.2 359.4
Cash Interest Paid 15.1 10.6 25.6